Illumina's September Swoon: Competition and Legal Woes

Illumina's stock just took another hit! Shares plunged after news of rising competition from China's MGI and a costly settlement with the Department of Justice. Is this a buying opportunity or a sign of deeper trouble for the genomics giant? We break down the factors driving Illumina's volatile year and what it means for investors. Hosted on Acast. See acast.com/privacy for more information.